The Medicines and Healthcare products Regulatory Agency (MHRA) and Health Research Authority (HRA) have announced the "largest package of reforms in more than 20 years."
The updates will include faster evaluations of first-in-human trials, a fast-track process for lower-risk notifiable trials and quick approvals for modifications, all while maintaining high safety standards.
The pair stated that the reforms will simplify starting lower-risk studies, enhance support for early-stage research and incorporate new methods such as using international safety data that meet UK standards and computer simulations to predict the behaviour of new medicines before patient testing.
These new clinical trial regulations will come into force today, 28 April 2026.
The regulators say they have already made significant strides in streamlining the clinical trial approval process, helping them surpass the government's goal of reducing setup times to 150 days.
Recent data shows that the MHRA and HRA have cut setup times from 169 days to 122 days for studies undergoing combined safety and ethical reviews, averaging just 41 days.
Additionally, a key innovation is the Route B substantial modification pathway, which was successfully piloted from October 2025 to March 2026.
This pathway allows certain modifications that don't raise safety concerns to be assessed more quickly and will be legally mandated (also starting April 28, 2026).
Under Route B, eligible modifications are automatically approved unless concerns are raised within 14 calendar days.
The MHRA and HRA say they have worked closely with patients, researchers, doctors and industry representatives to develop this framework, which emphasises participant safety and aims to enhance access and transparency.
For the first time in the UK, registering clinical trials and publishing summary results will be legal requirements.
Dr Zubir Ahmed, Health Innovation and Safety Minister, said: "This is a landmark moment for patients, researchers and our thriving life sciences sector that will make a real, tangible difference for thousands of people waiting for new treatments."
By introducing faster routes for lower-risk trials, embracing modern technology and making the system simpler to navigate, we are reinforcing the UK's position as one of the most attractive places in the world to invest in cutting-edge research.
MHRA Chief Executive, Lawrence Tallon, added: "These reforms to clinical trial regulations are a boost both for patients and industry investment in R&D in this country."
They will help to make the UK a more attractive, internationally competitive destination for both commercial and non-commercial clinical research. Most importantly, patients will benefit from earlier access to the latest, innovative medicines.
"We have listened carefully to the needs of patients, clinicians, researchers and industry to ensure we are delivering the most efficient, streamlined approvals process without compromising safety."
Chief Executive of the HRA, Matt Westmore, said: "The updated regulations will bring greater transparency, faster approvals for clinical trials and simpler approaches for low-risk trials – making it quicker and easier to set up and run trials while placing patients at the centre of medical research."
"Not only will the new framework speed up vital research that could lead to innovative and improved treatments for patients, but it will support a streamlined, joined-up and proportionate clinical research system."
The reforms are designed to speed up access to new medicines and boost the UK life sciences economy by making it easier to do research that people can trust.
The MHRA Clinical Trials (CT) Hub will provide practical guidance for sponsors to navigate the new regulations, featuring consolidated resources and recorded webinars shaped by feedback from various stakeholders.
Commenting on the reforms, Peter Rudd-Clarke, a partner at Osborne Clarke, said it would take time to see the effect changes to the regulations would have on the sector.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.